COMMUNIQUÉS West-GlobeNewswire

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
14/08/2026
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic into 2042 - AACR [...]
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
14/08/2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and [...]
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
14/08/2026
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
14/08/2026
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss [...]
TOMI Environmental Solutions, Inc. Reports Second Quarter 2026 Financial Results
14/08/2026
Company Delivers 118% Q2 Revenue Growth, Reaffirms Full-Year 2026 Guidance of $12 Million (113% YoY Growth) FREDERICK, Md., Aug. 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global [...]
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
14/08/2026
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose [...]
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
14/08/2026
Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the [...]
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
14/08/2026
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
14/08/2026
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – [...]
Sienna Announces August Dividend
14/08/2026
MARKHAM, Ontario, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site
14/08/2026
Strategic project expands Zorronet’s presence in defense technology test and evaluation environments and includes site infrastructure, systems integration, a dedicated command-and-control center and coordination with [...]
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
14/08/2026
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned during the current [...]
NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE
14/08/2026
Among Recent Developments: -Corporate Name Change- -Acquisition of Leading AI Energy Infrastructure Equipment/Services Provider- -Addition to Board of Renowned Energy Sector Executive- -Key Leadership Appointments at [...]
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
14/08/2026
Call scheduled for today, Friday, August 14, 2026, at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and [...]
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 [...]
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
14/08/2026
Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional [...]
Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme
14/08/2026
Cette soumission repose sur les résultats positifs d’efficacité et de sécurité de l’étude de Phase 3 VALOR NEW YORK & LYON, France, le 14 août 2026, Pfizer Inc. (NYSE: PFE) et Valneva SE (Nasdaq: VALN; Euronext [...]
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
14/08/2026
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced [...]
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
14/08/2026
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, [...]

Pages